GENOMIC TESTING

Latest News

January 28th 2019

TRK Inhibitors: A Tumor Agnostic Targeted Therapy

General Cancer

January 10th 2019

Broad-Panel NGS Benefits Metastatic NSCLC

By Anita Schaffer

November 15th 2018

Next-Generation Sequencing in Intimal Sarcoma

By Jason Roszik, PhD, MBA

September 14th 2018

Understanding Thrombotic Risk in ET and PV

By Laura Michaelis, MD

July 27th 2018

Integrating Molecular Pathology Into NSCLC Treatment Selection

By Ignacio I. Wistuba, MD

Latest Videos

Rucaparib in Platinum-Sensitive Ovarian Cancer

Rationale for Olaparib in Advanced Ovarian Cancer

Ovarian Cancer: Molecular Testing and PARP Inhibitors

PARP Inhibitors in Ovarian Cancer

Case 4: Maintenance Strategies in CLL

Case 4: iFCR in Untreated CLL

Case 4: iFCG in Untreated CLL

Case 4: A Young, Fit Patient With MRD-Positive CLL After Immunochemotherapy

Case 3: Therapeutic Approaches for Richter Transformation

Case 3: Progression on Ibrutinib Followed by Richter Transformation

CME Content

Video

Community Oncology Connections: Navigating PD-L1–Driven Decisions and ADC Integration in Frontline mTNBC | The Arizona Clinical Oncology Society

Neil M. Iyengar, MD; Kit Lu, MD

Virtual Event

Project ECHO®: Advancing Personalized Care Across the HR+/HER2– Breast Cancer Continuum

Webinar Series

Video

Community Oncology Connections: Navigating PD-L1–Driven Decisions and ADC Integration in Frontline mTNBC | Louisiana Oncology Society

Sarah M. Tolaney, MD, MPH; Parth Khade, MD

Video

Community Oncology Connections: Navigating PD-L1–Driven Decisions and ADC Integration in Frontline mTNBC | New Mexico Society of Clinical Oncology

Neil M. Iyengar, MD; Richard Zelkowitz, MD

Video

9th Annual School of Nursing Oncology™

Beth Faiman, PhD, MSN, APN-BC, BMTCN, AOCN, FAAN, FAPO; Beth Sandy, MSN, CRNP, FAPO; Lindsay Adkins, MSN, FNP-BC, BMTCN; Jeneth Aquino, DNP, FNP-BC; Casey Gormley, MSN, FNP-C, AOCNP; Heather J. Jackson, PhD, FNP-BC; Kelsey Martin, AG-ACNP-BC, AOCNP; Nerina T. McDonald, PA-C; Lauren Verity Moore, DNP, MSN, AGACNP-BC; Faith A. Mutale, DNP, CRNP; Tiffany Richards, PhD, ANP-BC, AOCNP; Emily Skotte, DNP, MSN, ACNP-BC; Leslie Smith, DNP, RN, APRN-CNS, AOCNS, BMTCN; Saneese Stephen, PA-C, MPAS; Sara M. Tinsley-Vance, PhD, APRN, AOCN

Virtual Event

Kentucky Society of Clinical Oncology

2 Sessions are Available!

Video

Hot Seat: How Experts Are Integrating the Latest Practice-Changing Data Into Their Breast Cancer Clinics

Tiffany A. Traina, MD, FASCO; Nour Abuhadra, MD; Joshua Z. Drago, MD, MS; Ruth O’Regan, MD; Vered Stearns, MD, FASCO; Neil Vasan, MD, PhD; Anna Weiss, MD

Virtual Event

South Carolina Oncology Society

2 Sessions are Available!

Video

Community Oncology Connections: Navigating PD-L1–Driven Decisions and ADC Integration in Frontline mTNBC | Missouri Oncology Society

Neil M. Iyengar, MD; Ajit K. Bisen, MD, MBA

Video

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | New Mexico Society of Clinical Oncology

Erika P. Hamilton, MD; Katherine Sanchez, MD

Video

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | Iowa Oncology Society

Wassim Mchayleh, MD, MBA, FACP; Trevor Feinstein, MD

Video

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | Louisiana Oncology Society

Virginia Kaklamani, MD, DSc

Virtual Event

Oncology Town Hall: Oral SERDs in HR+/HER2- Metastatic Breast Cancer – What the Latest Data Really Tell Us

Webinar Series

Multimedia

Beyond Primary End Points: Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer

Seth A. Wander, MD, PhD; Marla D. Lipsyc-Sharf, MD

Video

Medical Crossfire®: Mastering the Nuances of Early-Stage HR+/HER2- Breast Cancer—Expert Perspectives on Applying Modern Treatment Paradigms

Tiffany A. Traina, MD, FASCO; Kevin Kalinsky, MD MS, FASCO; Mark E. Robson, MD, FASCO; Rebecca Shatsky, MD

Video

Medical Crossfire™: Navigating the Expanding Arsenal of Endocrine Therapies for HR+/HER2- Metastatic Breast Cancer – How Can PROTAC ER Degradation Shift the Standard?

William J. Gradishar, MD, FASCO, FACP; Stephanie L. Graff, MD, FACP, FASCO; Cynthia X. Ma, MD, PhD

Video

Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP inhibition in Triple-Negative Breast Cancer

Hope S. Rugo, MD; Alison K. Conlin, MD; Marleen Kok, MD, PhD; Heather McArthur, MD, MPH

Video

Show Me the Data™: Personalizing First-Line and Maintenance Therapy in HER2+ Metastatic Breast Cancer to Extend Survival and Elevate Quality of Life

Sara A. Hurvitz, MD, FACP; Rena Callahan, MD; Michelle Melisko, MD; Paolo Tarantino, MD, PhD

Video

Module 4: Breast Surgery (2025)

Eleftherios (Terry) Mamounas, MD, MPH, FACS; Michael Alvarado, MD, MS; Puneet Singh, MD, MS, FACS, FSSO, CMQ

Video

Module 5: Breast Radiation Therapy (2025)

Douglas W. Arthur, MD, FABS, FASTRO; Eleanor E. Harris, MD, FASTRO; Kathleen Horst, MD

Video

Module 3: Pathology And Biomarkers (2025)

Joyce O’Shaughnessy, MD; Sunil S. Badve, MD, FRCPath; Claudine Isaacs, MD; Michael F. Press, MD, PhD

Video

Module 6: Adjuvant/Neoadjuvant Chemotherapy and Endocrine Therapy (2025)

Joyce O’Shaughnessy, MD; William J. Gradishar, MD, FASCO, FACP; N. Lynn Henry, MD, PhD, FASCO; Kevin Kalinsky, MD, MS; Joseph A. Sparano, MD; Sara Tolaney, MD, MPH

Video

Module 1: Breast Carcinogenesis & Management of High-Risk Disease (2025)

Joyce O’Shaughnessy, MD; Carol Fabian, MD; Rachel Freedman, MD, MPH; Anne Grabenstetter, MD; Claudine Isaacs, MD; Pedram Razavi, MD, PhD

Video

Module 7: Systemic Treatment Of Advanced/Metastatic Disease (2025)

William J. Gradishar, MD, FASCO, FACP; Ting Bao, MD, MS; Jennifer A. Ligibel, MD; Filipa Lynce, MD; Ruth O’Regan, MD, MSc

Video

Module 2: Breast Imaging (2025)

Joyce O’Shaughnessy, MD; Connie Lehman, MD, PhD, FACR; David M. Schuster, MD, FACR

Video

Module 8: Organ-Targeted Treatment of Metastatic Disease (2025)

Joyce O’Shaughnessy, MD; Michelle Melisko, MD; Beverly Moy, MD, MPH

Video

Module 9: Toxicity Management And Survivorship Considerations (2025)

Joyce O’Shaughnessy, MD; Laura Huppert, MD; Michelle Melisko, MD; Michelle Mollica, PhD, MPH, RN, OCN; Ann H. Partridge, MD, MPH

Video

(CPE Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

Michelle L. Taylor, ANP-BC; Emely Alfaro, DNP, RN, CNS, OCN; Paige Griffith, CRNP; Beth Sandy, MSN, CRNP, FAPO

Video

Expanding Options, Evolving Challenges in Advanced HR+/HER2– Breast Cancer: How Experts Apply the Latest Data

Kevin Kalinsky, MD, MS; Adam Brufsky, MD, PhD; Kelly Elizabeth McCann, MD, PhD; Sara Nunnery, MD, MSCI

Video

Medical Crossfire®: Optimizing 𝘌𝘚𝘙1 Mutation Detection and Next-Generation Endocrine Therapy Integration in HR+/HER2– Breast Cancer

VK Gadi, MD, PhD; Neil M. Iyengar, MD; Heather McArthur, MD, MPH

Video

Facilitating Precision Pathways: Surgical Considerations in Breast Cancer for Tackling Barriers to Genetic Testing and Targeted Therapies

Patrick I. Borgen, MD; Don S. Dizon, MD, FACP, FASCO; Kevin S. Hughes, MD, FACS; Banu Arun, MD, FASCO

Video

Coffee Talk: Charting New Pathways with HER2 and TROP2 Therapies – From Early to Advanced Breast Cancer

Hope S. Rugo, MD, FASCO; Paolo Tarantino, MD, PhD; Alastair Thompson, MD, MBChB, BSc (Hons), FRCS (Ed), FACS

Multimedia

Community Practice Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer

Neil M. Iyengar, MD; Sara M. Tolaney, MD, MPH

Video

Virtual Hot Seat: How the Experts Target the PI3K/AKT/mTOR Pathway in HR+/HER2– Metastatic Breast Cancer

Rebecca Shatsky, MD; Maxwell Roger Lloyd, MD; Sarah Sammons, MD; Sherry Shen, MD

More News

Molecular Profiling to Inform Treatment Decisions for Patients With NSCLC

ByGiorgio V. Scagliotti, MD

July 27th 2018

Giorgio Vittorio Scagliotti, MD, PhD, chief of the Medical Oncology Division at the S. Luigi Hospital, Orbassano (Torino), and head of the Department of Oncology at University of Torino, Italy, discusses the utilization of molecular profiling to inform treatment decisions for patients with non-small cell lung cancer.

PARP Inhibitor Combinations and Future of Ovarian Cancer

June 22nd 2018

Sequencing Therapies for Ovarian Cancer Progression

June 22nd 2018

EOC: Maintenance Therapy With PARP Inhibitors

June 22nd 2018

Clinical Use of Niraparib in Ovarian Cancer

June 22nd 2018

Next-Generation Sequencing for Metastatic NSCLC Associated With Substantial Cost Savings

May 16th 2018

According to findings released ahead of the 2018 ASCO Annual Meeting, the use of next-generation sequencing (NGS) for patients with metastatic non–small cell lung cancer (NSCLC) can save Center for Medicare and Medicaid Services (CMS) payers $1.4 million to $2.1 million. The findings additionally showed that NGS saved commercial insurance providers more than $250,000.<br />  

GENOMIC TESTING

Latest News

Latest Videos

Rucaparib in Platinum-Sensitive Ovarian Cancer

Rationale for Olaparib in Advanced Ovarian Cancer

Ovarian Cancer: Molecular Testing and PARP Inhibitors

PARP Inhibitors in Ovarian Cancer

Case 4: Maintenance Strategies in CLL

Case 4: iFCR in Untreated CLL

Case 4: iFCG in Untreated CLL

Case 4: A Young, Fit Patient With MRD-Positive CLL After Immunochemotherapy

Case 3: Therapeutic Approaches for Richter Transformation

Case 3: Progression on Ibrutinib Followed by Richter Transformation

CME Content

Community Oncology Connections: Navigating PD-L1–Driven Decisions and ADC Integration in Frontline mTNBC | The Arizona Clinical Oncology Society

Project ECHO®: Advancing Personalized Care Across the HR+/HER2– Breast Cancer Continuum

Community Oncology Connections: Navigating PD-L1–Driven Decisions and ADC Integration in Frontline mTNBC | Louisiana Oncology Society

Community Oncology Connections: Navigating PD-L1–Driven Decisions and ADC Integration in Frontline mTNBC | New Mexico Society of Clinical Oncology

9th Annual School of Nursing Oncology™

Kentucky Society of Clinical Oncology

Hot Seat: How Experts Are Integrating the Latest Practice-Changing Data Into Their Breast Cancer Clinics

South Carolina Oncology Society

Community Oncology Connections: Navigating PD-L1–Driven Decisions and ADC Integration in Frontline mTNBC | Missouri Oncology Society

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | New Mexico Society of Clinical Oncology

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | Iowa Oncology Society

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | Louisiana Oncology Society

Oncology Town Hall: Oral SERDs in HR+/HER2- Metastatic Breast Cancer – What the Latest Data Really Tell Us

Beyond Primary End Points: Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer

Medical Crossfire®: Mastering the Nuances of Early-Stage HR+/HER2- Breast Cancer—Expert Perspectives on Applying Modern Treatment Paradigms

Medical Crossfire™: Navigating the Expanding Arsenal of Endocrine Therapies for HR+/HER2- Metastatic Breast Cancer – How Can PROTAC ER Degradation Shift the Standard?

Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP inhibition in Triple-Negative Breast Cancer

Show Me the Data™: Personalizing First-Line and Maintenance Therapy in HER2+ Metastatic Breast Cancer to Extend Survival and Elevate Quality of Life

Module 4: Breast Surgery (2025)

Module 5: Breast Radiation Therapy (2025)

Module 3: Pathology And Biomarkers (2025)

Module 6: Adjuvant/Neoadjuvant Chemotherapy and Endocrine Therapy (2025)

Module 1: Breast Carcinogenesis & Management of High-Risk Disease (2025)

Module 7: Systemic Treatment Of Advanced/Metastatic Disease (2025)

Module 2: Breast Imaging (2025)

Module 8: Organ-Targeted Treatment of Metastatic Disease (2025)

Module 9: Toxicity Management And Survivorship Considerations (2025)

(CPE Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

Expanding Options, Evolving Challenges in Advanced HR+/HER2– Breast Cancer: How Experts Apply the Latest Data

Medical Crossfire®: Optimizing 𝘌𝘚𝘙1 Mutation Detection and Next-Generation Endocrine Therapy Integration in HR+/HER2– Breast Cancer

Facilitating Precision Pathways: Surgical Considerations in Breast Cancer for Tackling Barriers to Genetic Testing and Targeted Therapies

Coffee Talk: Charting New Pathways with HER2 and TROP2 Therapies – From Early to Advanced Breast Cancer

Community Practice Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer

Virtual Hot Seat: How the Experts Target the PI3K/AKT/mTOR Pathway in HR+/HER2– Metastatic Breast Cancer

More News

Molecular Profiling to Inform Treatment Decisions for Patients With NSCLC

PARP Inhibitor Combinations and Future of Ovarian Cancer

Sequencing Therapies for Ovarian Cancer Progression

EOC: Maintenance Therapy With PARP Inhibitors

Clinical Use of Niraparib in Ovarian Cancer

Next-Generation Sequencing for Metastatic NSCLC Associated With Substantial Cost Savings

Case 3: Response to Frontline Therapy and Toxicity Management

Case 3: Elderly Patient With CLL, Mutated TP53 and NOTCH, Unmutated IgHV

Case 2: Treatment Options: Venetoclax +/- Rituximab

Case 2: 17p-Deleted CLL Progressing on Ibrutinib Therapy

Case 1: Treatment Decision: Ibrutinib Monotherapy

Case 1: Targeted Therapy: Ibrutinib for Newly Diagnosed CLL

Case 1: Prognostic Features and Chemoimmunotherapy Treatment Options

Case 1: An Elderly Patient With Newly Diagnosed High-Risk CLL

Management of Chronic Lymphocytic Leukemia

Trending on Targeted Onc

FDA Approves Durvalumab-EV Combo, Expanding MIBC Treatment Options

New ACS Guidelines Push for Earlier Prostate Cancer Screening

Survey Highlights NMIBC Care Challenges Among US Military Service, Veterans

Dr Dasari on Sequencing RLT, Cabozantinib, and Everolimus in NETs

Expanding the Evidence on Lung Cancer Prevention